Immune checkpoint blockade (ICB), particularly targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1, has demonstrated promising clinical benefits as monotherapy for advanced HCC patients, and combining it with other therapeutic agents may further enhance its effectiveness [2–4]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.